MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care

Core Insights - MannKind Corporation has received FDA approval for the FUROSCIX On-body Infusor for pediatric patients, expanding its treatment options for chronic heart failure and chronic kidney disease [1][3] - The company also announced that the FDA accepted a Supplemental NDA for the FUROSCIX ReadyFlow Autoinjector, with a target action date set for July 26, 2026 [2] - The ReadyFlow Autoinjector is designed to deliver a subcutaneous dose of furosemide in under 10 seconds, significantly faster than the On-body Infusor, which takes 5 hours [3] Company Overview - MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic products for endocrine and orphan lung diseases in the US [4]